Stay updated on ACP-196 + Pembrolizumab in Hematologic Malignancies Clinical Trial
Sign up to get notified when there's something new on the ACP-196 + Pembrolizumab in Hematologic Malignancies Clinical Trial page.

Latest updates to the ACP-196 + Pembrolizumab in Hematologic Malignancies Clinical Trial page
- Check5 days agoNo Change Detected
- Check12 days agoNo Change Detected
- Check19 days agoChange DetectedRevision updated from v3.2.0 to v3.3.2 in the page footer, with no visible changes to the study details. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check26 days agoChange DetectedThe government funding operating-status notice has been removed from the page.SummaryDifference0.3%

- Check49 days agoChange DetectedThe screenshots show only minor UI/layout updates without any changes to core study content such as title, conditions, interventions, outcomes, eligibility criteria, or enrollment. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check70 days agoChange DetectedUpdate refresh: new operating-status notice and newer date/version metadata; removal of older last-update and disease-specific items.SummaryDifference4%

- Check77 days agoChange DetectedUpdated terminology from Plasma cell myeloma to Multiple myeloma and bumped the revision from v3.0.2 to v3.1.0.SummaryDifference0.2%

- Check92 days agoChange DetectedRevision updated from v3.0.1 to v3.0.2; the 'Back to Top' element was removed. No substantive changes to core content, pricing, or availability.SummaryDifference0.2%

Stay in the know with updates to ACP-196 + Pembrolizumab in Hematologic Malignancies Clinical Trial
Enter your email address, and we'll notify you when there's something new on the ACP-196 + Pembrolizumab in Hematologic Malignancies Clinical Trial page.